CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
SOHO 最新进展与后续问题 | CAR-T 细胞在 T 细胞急性淋巴细胞白血病和淋巴母细胞淋巴瘤中
英文原题：SOHO State of the Art Updates and Next Questions | CAR T Cells in T Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
查看英文原题
SOHO State of the Art Updates and Next Questions | CAR T Cells in T Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 治疗复发/难治性B系恶性肿瘤疗效优异，但将其拓展至T细胞癌症需克服独特障碍。近年来，多个策略已在临床前模型中开发，部分也进入难治性T细胞恶性肿瘤临床试验，初步结果令人鼓舞。本文综述阻碍CAR-T 治疗T细胞急性淋巴细胞白血病/淋巴瘤成功的主要问题、潜在解决方案，以及该领域临床前和临床开发的最新进展。
展开英文摘要原文
Chimeric antigen receptor (CAR T) therapy produced excellent activity in patients with relapsed/refractory B-lineage malignancies.
However, extending these therapies to T cell cancers requires overcoming unique challenges. In the recent years, multiple approaches have been developed in preclinical models and some were tested in clinical trials in patients with treatment-refractory T-cell malignanices with promising early results.
Here, we review main hurdles impeding the success of CAR T therapy in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL), discuss potential solutions, and summarize recent progress in both preclinical and clinical development of CAR T therapy for these diseases.
论文信息
- 作者
- Shmidt D、Mamonkin M
- 第一作者单位
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX.United States
- 通讯作者单位
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX. Electronic address: mamonkin@bcm.edu.United States
- 文献类型
- 综述
- 期刊
- Clinical lymphoma, myeloma & leukemia2025 Feb
- 原文标识
- PubMed 38955579 · DOI 10.1016/j.clml.2024.05.018